NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

21.05M

Vuru Grade

31.66/100

Current Price

$2.30
+0.00 (+0.00%)

Company Metrics

  • P/E 0
  • P/S 3.79
  • P/B 27.9
  • EPS -5.95
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / 0%
  • Avg. Vol. 44,905.00
  • Shares 2.78M
  • Market Cap. 21.05M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 06/13/16; Press Release. NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer.
NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
This Weeks Broker Views For NovaBay Pharmaceuticals, Inc. (NBY)
Fiscal Standard - Jun 19, 2016
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market.
Don't Miss: NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Tenneco Inc. (NYSE ...
Benchmark Monitor - Jul 18, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) traded 105052 shares on last trading day with closing price of $2.39. Company gross margin stands at 69.00% whereas its return on investment (ROI) is 618.40%.
Novabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Short Interest Decreased By ... - Consumer Eagle
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two ...
Business Wire (press release) - Apr 6, 2016
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova┬« Lid and Lash Cleanser for the domestic eye care market, announces that it has entered into a securities purchase ...
Increased Stock Volatility Watch: NovaBay Pharmaceuticals, Inc. (:NBY)
Engelwood Daily - Jul 20, 2016
Shares of NovaBay Pharmaceuticals, Inc. (:NBY) are displaying high volatlity in today's session as the stock has changed 3.26%, clocking in at $2.33 with a recent bid.
NovaBay Pharmaceuticals, Inc. (NBY) Falls in Pre-market Before Skyrocketing ...
Independent Reporter - Dec 21, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) fell considerably in pre-market trading this morning, before skyrocking after the market opened.
NovaBay Pharma (NBY) Names Mark Sieczkarek as Permanent CEO
StreetInsider.com - Jun 13, 2016
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announces the appointment of Mark M. Sieczkarek as President and Chief Executive Officer, effectively immediately.
Noting Unusual Volume on Shares of NovaBay Pharmaceuticals, Inc. (:NBY)
Engelwood Daily - Jul 15, 2016
Shares of NovaBay Pharmaceuticals, Inc. (:NBY) are experiencing unusual volume during today's trading. While the stock price moved along with the volume change, shares are touching $2.33 at the time of writing.
Trading Action Review: Watching Unusual Volume on NovaBay Pharmaceuticals, Inc ...
Engelwood Daily - Jul 19, 2016
Shares of NovaBay Pharmaceuticals, Inc. (:NBY) are experiencing unusual volume during today's trading. While the stock price moved along with the volume change, shares are touching $2.20 at the time of writing.